VMD
Viemed Healthcare, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$9.08
+0.78%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 301.6M | 270.3M | 224.3M | 183.0M | 138.8M |
| Cost of Revenue | 129.1M | 114.8M | 91.1M | 70.2M | 54.2M |
| Gross Profit | 172.5M | 155.5M | 133.2M | 112.8M | 84.7M |
| Operating Expenses | |||||
| R&D Expense | 2.5M | 3.0M | 3.1M | 2.8M | 2.7M |
| SG&A Expense | 142.6M | 130.5M | 112.5M | 93.7M | 73.4M |
| General & Admin Expense | 68.6M | 130.5M | 112.5M | 93.7M | 73.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.0M | 1.2M | (249.0K) | 1.9M | 369.0K |
| Total Operating Expenses | 148.0M | 134.7M | 115.3M | 98.5M | 76.4M |
| Cost and Expenses | 277.0M | 249.6M | 206.4M | 168.7M | 130.6M |
| Operating Income (EBIT) | 24.6M | 20.7M | 17.9M | 14.3M | 8.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.4M | 1.2M | 776.0K | 424.0K | 197.0K |
| Net Interest Income | (1.4M) | (1.2M) | (776.0K) | (424.0K) | (197.0K) |
| Other Non-Op Income/Expense | (3.4M) | 1.1M | (1.7M) | 61.0K | 738.0K |
| Non-Operating Income (excl Interest) | 1.2M | (2.2M) | 954.0K | (485.0K) | (935.0K) |
| EBT (Pre-Tax Income) | 21.2M | 21.8M | 16.2M | 14.4M | 9.0M |
| Income Tax Expense | 6.2M | 6.4M | 4.8M | 4.1M | 2.8M |
| Bottom Line | |||||
| Net Income | 14.5M | 14.9M | 11.3M | 10.2M | 6.2M |
| Earnings from Cont. Ops | 15.0M | 15.4M | 11.4M | 10.2M | 6.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 14.5M | 14.9M | 11.3M | 10.2M | 6.2M |
| Per Share | |||||
| Basic EPS | $0.38 | $0.38 | $0.29 | $0.27 | $0.15 |
| Diluted EPS | $0.36 | $0.37 | $0.28 | $0.25 | $0.15 |
| Revenue Per Share | $7.89 | $6.95 | $5.79 | $4.77 | $3.59 |
| Shares | |||||
| Basic Shares Outstanding | 38.2M | 38.9M | 38.8M | 38.4M | 38.7M |
| Diluted Shares Outstanding | 41.1M | 40.8M | 40.8M | 40.4M | 39.8M |
| Profitability Metrics | |||||
| EBITDA | 53.6M | 51.6M | 42.3M | 36.7M | 24.8M |
| D&A | 30.3M | 28.6M | 25.4M | 21.9M | 15.6M |
| EBIT | 23.4M | 22.9M | 16.9M | 14.8M | 9.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026